Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VG2025 in Advanced Intrahepatic Cholangiocarcinoma
NCT07522476Phase 2Recruiting
- Sponsor
- Virogin Biotech
- Start
- Aug 2026
- Primary completion
- Jan 2028
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of VG2025 in intrahepatic cholangiocarcinoma (ICC), sponsored by Virogin Biotech. Started Aug 2026; status: recruiting.
02
Drugs
VG2025
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT07522476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07522476.